UBS Group Raises United Therapeutics (NASDAQ:UTHR) Price Target to $370.00

United Therapeutics (NASDAQ:UTHRFree Report) had its price target lifted by UBS Group from $300.00 to $370.00 in a research report sent to investors on Monday, Benzinga reports. They currently have a buy rating on the biotechnology company’s stock.

A number of other equities analysts also recently weighed in on UTHR. The Goldman Sachs Group boosted their target price on United Therapeutics from $218.00 to $240.00 and gave the stock a neutral rating in a research note on Friday, May 3rd. HC Wainwright reissued a buy rating and issued a $300.00 price objective on shares of United Therapeutics in a research report on Thursday, May 2nd. Oppenheimer raised their target price on United Therapeutics from $375.00 to $400.00 and gave the company an outperform rating in a research report on Thursday, May 2nd. Wells Fargo & Company boosted their price target on shares of United Therapeutics from $325.00 to $350.00 and gave the stock an overweight rating in a report on Wednesday, June 12th. Finally, JPMorgan Chase & Co. increased their price target on shares of United Therapeutics from $280.00 to $300.00 and gave the company an overweight rating in a research report on Tuesday, May 21st. One analyst has rated the stock with a hold rating and eleven have given a buy rating to the company. According to data from MarketBeat.com, United Therapeutics has a consensus rating of Moderate Buy and a consensus price target of $318.00.

View Our Latest Stock Report on United Therapeutics

United Therapeutics Price Performance

Shares of NASDAQ:UTHR opened at $329.25 on Monday. The company has a current ratio of 3.77, a quick ratio of 3.64 and a debt-to-equity ratio of 0.04. The stock has a market cap of $14.61 billion, a PE ratio of 15.57, a price-to-earnings-growth ratio of 1.39 and a beta of 0.55. The stock’s fifty day simple moving average is $287.54 and its two-hundred day simple moving average is $248.48. United Therapeutics has a 1-year low of $208.62 and a 1-year high of $329.93.

United Therapeutics (NASDAQ:UTHRGet Free Report) last released its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported $6.17 earnings per share for the quarter, beating analysts’ consensus estimates of $5.63 by $0.54. United Therapeutics had a net margin of 42.05% and a return on equity of 18.72%. The company had revenue of $677.70 million for the quarter, compared to analyst estimates of $620.31 million. During the same period last year, the firm earned $4.86 earnings per share. The firm’s revenue was up 33.7% on a year-over-year basis. As a group, analysts forecast that United Therapeutics will post 24.73 EPS for the current fiscal year.

Insiders Place Their Bets

In other news, CEO Martine A. Rothblatt sold 3,600 shares of the business’s stock in a transaction that occurred on Tuesday, April 16th. The shares were sold at an average price of $232.05, for a total value of $835,380.00. Following the sale, the chief executive officer now owns 130 shares of the company’s stock, valued at $30,166.50. The transaction was disclosed in a legal filing with the SEC, which is accessible through the SEC website. In other news, CEO Martine A. Rothblatt sold 3,600 shares of United Therapeutics stock in a transaction on Tuesday, April 16th. The stock was sold at an average price of $232.05, for a total value of $835,380.00. Following the completion of the transaction, the chief executive officer now directly owns 130 shares in the company, valued at $30,166.50. The sale was disclosed in a document filed with the SEC, which is available through the SEC website. Also, Director Christopher Patusky sold 1,310 shares of the stock in a transaction dated Tuesday, May 14th. The stock was sold at an average price of $264.35, for a total value of $346,298.50. The disclosure for this sale can be found here. Insiders sold 100,884 shares of company stock worth $27,604,643 over the last quarter. 12.50% of the stock is currently owned by company insiders.

Hedge Funds Weigh In On United Therapeutics

A number of large investors have recently modified their holdings of the company. Rise Advisors LLC purchased a new stake in United Therapeutics in the 1st quarter worth approximately $32,000. GAMMA Investing LLC bought a new position in shares of United Therapeutics in the fourth quarter worth $43,000. Benjamin F. Edwards & Company Inc. increased its holdings in shares of United Therapeutics by 63.6% in the first quarter. Benjamin F. Edwards & Company Inc. now owns 301 shares of the biotechnology company’s stock worth $69,000 after purchasing an additional 117 shares during the period. Janiczek Wealth Management LLC raised its position in shares of United Therapeutics by 21.1% in the first quarter. Janiczek Wealth Management LLC now owns 482 shares of the biotechnology company’s stock worth $111,000 after buying an additional 84 shares in the last quarter. Finally, Blue Trust Inc. boosted its stake in United Therapeutics by 10.0% during the fourth quarter. Blue Trust Inc. now owns 504 shares of the biotechnology company’s stock valued at $114,000 after buying an additional 46 shares during the period. 94.08% of the stock is currently owned by institutional investors.

About United Therapeutics

(Get Free Report)

United Therapeutics Corporation, a biotechnology company, engages in the development and commercialization of products to address the unmet medical needs of patients with chronic and life-threatening diseases in the United States and internationally. The company offers Tyvaso DPI, an inhaled dry powder via pre-filled and single-use cartridges; Tyvaso, an inhaled solution via ultrasonic nebulizer; Remodulin (treprostinil) injection to treat patients with pulmonary arterial hypertension (PAH) to diminish symptoms associated with exercise; Orenitram, a tablet dosage form of treprostinil, to delay disease progression and improve exercise capacity in PAH patients; and Adcirca, an oral PDE-5 inhibitor to enhance the exercise ability in PAH patients.

Featured Stories

Analyst Recommendations for United Therapeutics (NASDAQ:UTHR)

Receive News & Ratings for United Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for United Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.